ArticleFrontiers in oncology2022
A Novel Radiotherapeutic Approach to Treat Bulky Metastases Even From Cutaneous Squamous Cell Carcinoma: Its Rationale and a Look at the Reliability of the Linear-Quadratic Model to Explain Its Radiobiological Effects.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Bibliometric analysis of global research trends in spatially fractionated radiotherapy.Frontiers in oncology · 2026Pooled it
- Dosimetric comparison of pipe-joint versus conventional VMAT for lattice radiotherapy in bulky tumors: a retrospective planning study.Radiation oncology (London, England) · 2026Article
- A single-field-each-peak optimization method for motion-robust proton LATTICE therapy.Medical physics · 2026Article
- Dose optimization with fully flexible vertex positioning for LATTICE radiotherapy.Medical physics · 2026Article
- SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.Frontiers in oncology · 2026Article
- Emerging strategies in radiation therapy: promises and challenges of spatial fractionation, ultra-high dose rates, and nanoparticles.Journal of physics D: Applied physics · 2025Review
- Article
- A fully flexible joint lattice position and dose optimization method for LATTICE therapy.ArXiv · 2025Article
- Progress of the application of spatially fractionated radiation therapy in palliative treatment of tumors.Discover oncology · 2025Review
- Feasibility of optimal vertex size and spacing for lattice radiotherapy implementation using helical tomotherapy.Frontiers in oncology · 2025Article
- Review
- Feasibility planning study of lattice radiotherapy for palliation in bulky tumors.Precision radiation oncology · 2024Article
- Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: preliminary results from a single-center study.Discover oncology · 2024Article
- Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression.Cancers · 2024Review
- Time-Related Outcome Following Palliative Spatially Fractionated Stereotactic Radiation Therapy (Lattice) of Large Tumors - A Case Series.Advances in radiation oncology · 2024Article
- The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results.Journal of personalized medicine · 2024Article
- Computational Approach for Spatially Fractionated Radiation Therapy (SFRT) and Immunological Response in Precision Radiation Therapy.Journal of personalized medicine · 2024Article
- Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.Theranostics · 2024Article
- Mathematical modeling of the synergistic interplay of radiotherapy and immunotherapy in anti-cancer treatments.Frontiers in immunology · 2024Article
- Immune Priming with Spatially Fractionated Radiation Therapy.Current oncology reports · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metastatic cutaneous squamous cell carcinoma (cSCC) is a very rare condition. The lack of definition of an oligometastatic subgroup means that there is no consensus for its treatment, unlike the mucosal head and neck counterpart. Like the latter, the cutaneous form is able to develop bulky tumor masses. When this happens, the classic care approach is just for palliative intent due to a likely unfavorable benefit-risk balance typical of aggressive treatments. Here we proposed a novel radiotherapy (RT) technique to treat bulky metastases from cSCC in the context of an overall limited tumor burden and tried to explain its clinical outcome by the currently available mathematical radiobiological and Methods: We treated a case of facial cSCC with three metastases: two of them by classic stereotactic RT and the other by lattice RT supported by metabolic imaging ( Results: We observed a clinical complete response in all three disease sites; the bulky metastasis actually regressed more rapidly than the other two treated by stereotactic RT. For the large lesion, NTCP predictions were good for all four different plans but even significantly better for the lattice RT plan. Neither the classic TCP nor the Conclusions: PET-guided lattice RT might be safe and effective for the treatment of bulky lesions from cSCC. There might be some need for complex mathematical radiobiological models that are able to take into account any immune system's role in order to explain the possible mechanisms of the tumor response to radiation and the relevant key points to enhance it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.